Clinical trials: Benign Meningioma
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Acoustic Schwannoma, Adult Anaplastic Meningioma
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma
- Trial name
- NCT01125046
- Testing
- bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment.
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma
- Trial name
- NCT02255461
- Testing
- palbociclib isethionate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pediatric Brain Tumor Consortium
Central Nervous System Lymphoma
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967200
- Testing
- laboratory biomarker analysis, pharmacogenomic studies
- Where
- 2 sites in France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Montpellier
Investigate the Effect of External Lumbar Cistern Drainage in Preventing Postoperative Hydrocephalus in Patients Who Have Undergone Meningioma Surgery
Impact of External Drainage of the Lumbar Cistern in Patients With Hydrocephalus Following Meningioma Surgery and Its Influence on Patient Satisfaction
This study aims to investigate the effect of external lumbar cistern drainage in preventing postoperative hydrocephalus in patients who have undergone meningioma surgery and its impact on patient satisfaction.
- Trial name
- NCT06383169
- Where
- China
- Volunteers
- 86 people
- Sponsor
- First Hospital of Zhangjiakou City
Brain Neoplasms, Malignant, Brain Neoplasms, Benign
Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
RATIONALE: Pioglitazone hydrochloride may be effective treatment for cognitive dysfunction caused by radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of pioglitazone hydrochloride in…
- Conditions
- Brain Neoplasms, Malignant, Brain Neoplasms, Benign, Malignant Meningioma, Glioblastoma Multiforme
- Trial name
- NCT01151670
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Meningiomas
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
This research study is studying targeted immunotherapies as a possible treatment for recurrent meningioma. The names of the study interventions involved in this study are nivolumab and ipilimumab.
- Trial name
- NCT02648997
- Testing
- Nivolumab - 240 mg, Ipilimumab - 1 mg/kg, Nivolumab - 480 mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Meningioma, Malignant
Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma
This research study is studying a drug as a possible treatment for High Grade Meningioma.
- Trial name
- NCT04728568
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Tiantan Hospital
Cavernous Sinus Syndrome, Cavernous Sinus Meningioma
Role of 18F-FDG PET/CT in the Evaluation of Cavernous Sinus Syndrome: a Pilot Study
Cavernous sinus syndrome (CSS) can be caused by a wide range of inflammatory, malignant, benign, vascular and miscellaneous disorders.
- Conditions
- Cavernous Sinus Syndrome, Cavernous Sinus Meningioma, Cavernous Sinus Lesions
- Trial name
- NCT06721130
- Testing
- FDG radiotracer
- Where
- India
- Volunteers
- 54 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Central Nervous System Neoplasms, Glioblastoma
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting…
- Conditions
- Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma
- Trial name
- NCT04541082
- Testing
- ONC206
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Jazz Pharmaceuticals
Brain Neoplasms, Meningioma
Preoperative Embolization for Highly Vascular Brain Tumors
Highly vascular brain tumors, including meningiomas, hemangioblastomas, and certain metastases, have a rich blood supply that can lead to substantial blood loss and technical difficulties during surgical removal.
- Conditions
- Brain Neoplasms, Meningioma, Hemangioblastoma, Brain Metastases
- Trial name
- NCT07823985
- Testing
- Preoperative Endovascular Embolization
- Volunteers
- 55 people
- Sponsor
- Assiut University
Meningioma
Multicenter Evaluation in Patients With MEningiomas of the Response to Treatment With 177LUTEtium-oxodotreotide
Meningiomas are the most common primary tumors of the central nervous system, representing more than a third of tumors.Current conventional treatments for meningioma are surgery and radiotherapy.
- Trial name
- MELUTE (NCT06255249)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Central Hospital, Nancy, France
Malignant Meningioma
γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma
This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment…
- Trial name
- NCT07172178
- Testing
- γδ T-PD-1 Ab cells
- Volunteers
- 12 people
- Sponsor
- Nanjing Medical University
Brain Tumor, Primary, Meningioma
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination…
- Conditions
- Brain Tumor, Primary, Meningioma, Schwannoma, Pituitary Adenoma
- Trial name
- SOLOMON (NCT05254197)
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seoul National University Hospital
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Bevacizumab may reduce CNS side effects caused by radiation therapy. This randomized phase II trial is studying how well bevacizumab works in reducing CNS side effects in patients who have undergone radiation therapy to the brain…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT00492089
- Testing
- bevacizumab, magnetic resonance imaging, quality-of-life assessment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
CNS Tumors, Meningioma
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including esthesioneuroblastoma, hemangioblastoma, medulloblastoma…
- Conditions
- CNS Tumors, Meningioma, Esthesioneuroblastoma, Hemangioblastoma
- Trial name
- DOMINO-START (NCT04081701)
- Testing
- Ga68-DOTATATE-PET/MRI
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Meningioma
Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin
Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and treatement of the patients follow up in CHRU of…
- Trial name
- MAP (NCT04109404)
- Where
- France
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Meningioma
Information Presentation Formats
Prevention and early detection of medical problems can greatly reduce health care costs, yet time and again, people avoid or ignore services that could help detect medical problems early enough to prevent or reduce the severity…
- Trial name
- NCT02267928
- Testing
- Check Symptoms, Uncheck Symptoms, Experienced
- Where
- United States
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Carnegie Mellon University
Brain and Central Nervous System Tumors
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in treating young patients with recurrent or…
- Trial name
- NCT01158300
- Testing
- VEGF inhibitor PTC299
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pediatric Brain Tumor Consortium
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00363272
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)